Spearheading Nordic life science

Investments in innovative life science companies can yield high returns, but they also demand a great deal in terms of industry expertise and are often associated with a need for risk diversification.  

As a shareholder in Karolinska Development, you spread the risks between a number of carefully selected Nordic life science companies developing potentially ground-breaking treatments with high commercial potential or which are already in an early launch phase.

Our employees have extensive experience of research, development, financing and commercialisation of pharmaceutical and medtech projects. This expertise enables us to select attractive investment objects, to monitor the development of our portfolio companies, and to ensure that they have the right team composition and structure – both in order to progress the projects and to secure value-generating licensing deals, divestments, or IPOs, based on their successes.

Our portfolio

Please follow this link to read more about our portfolio.